Loading patent…
OwnerUlrich Schubert, Hans Will +1inventors
InventorsUlrich Schubert, Hans Will, Hüseyin Sirma
Estimating the term…
The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share the common property of inhibiting the 26S proteasome in cells. These substance classes include, in particular, proteasome inhibitors which affect the activities of the ubiquitin/proteasome pathway, in particular the enzymic activities of the 26S and the 20S proteasome complex. The application of the invention lies in the antiviral therapy of Flaviviridae infections, especially in preventing the establishment and maintenance of a chronic hepatitis C virus infection and a hepatopathogenesis which is associated therewith.
1-43. (canceled)
A method of treating a disease in a human or an animal, caused by Flaviviridae, comprising administering to a human or an animal infected with Flaviviridae, an agent effective to inhibit at least one of (a) release;
A method of effectively treating and controlling HCV-induced hepatitides, flavivirus-induced fever, hemorrhages and encephalitides and pestivirus-induced diseases by the directed administration of an agent for inhibiting at least one of release, maturation and replication of a member of the Flaviviridae family selected from Flavivirus or Pestivirus and Hepacivirus-wherein, the agent comprises, as an active component, at least one proteasome inhibitor in a pharmaceutical preparation, wherein the agent is used for the treatment and prophylaxis of HCV-induced hepatitides, flavivirus-induced fever, hemorrhages, leukopenia, thrombocytopenia, diarrheal diseases encephalitides or pestivirus-induced diseases, wherein the proteasome inhibitor
A method of producing agents for inhibiting the release, maturation and replication of Flaviviridae with at least one proteasome inhibitor, wherein the agent is for inhibiting at least one of release, maturation and replication of a member of the Flaviviridae family selected from Flavivirus or Pestivirus and Hepacivirus, wherein the agent comprises, as an active component, at least one proteasome inhibitor in a pharmaceutical preparation,
The method of claim 75, wherein the agent comprises at least one proteasome inhibitor for producing pharmaceuticals for the treatment and prophylaxis of HCV-induced hepatitides, flavivirus-induced fever, hemorrhages and encephalitides and pestivirus-induced diseases.
Dependencies are inferred from the claim text.